Promoter hypermethylation of key HRR genes, especially BRCA1 and RAD51C, can silence gene expression and induce HRD, with prevalence reaching up to 60% in TNBC and 1–15% in ovarian cancer [46,47]. The gene discussed is RAD51C; the disease is ovarian carcinoma.